Clinical Trial Update: Effect of Privigen Against Graft Loss [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Privigen for prevention of graft loss in kidney transplant recipients has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Privigen (intravenous immunoglobulin (IVIG))

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Kidney Transplantation | Phase 3 | Status: COMPLETED